Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease

Introduction: Remission rates in patients with Crohn's disease (CD) suggest a therapeutic ceiling with one advanced targeted treatment, representing an unmet need. Dual targeted therapy may provide a more effective treatment approach. Methods: The primary objective of VICTRIVA (NCT06227910), a rando...

詳細記述

書誌詳細

主要な著者:	Silvio Danese, Bruce E. Sands, Brian G. Feagan, Vipul Jairath, Remo Panaccione, Laurent Peyrin-Biroulet, Peter M. Irving, Stefan Schreiber, Iris Dotan, Marc Ferrante, Geert R. D'Haens, Stephen Jones, Marcelo Freire, Dirk Lindner, Shashi Adsul, Pooja Oberai, Jean-Frédéric Colombel
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-12-01
シリーズ:	Contemporary Clinical Trials Communications
主題:	Crohn's disease Phase 3b Methodology Placebo Upadacitinib Vedolizumab
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2451865425001486
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!